Brief: Alteogen Announces Completion Of Phase 1 Clinical Trial Of Aflibercept Biosimilar In Wet AMD Patients
08/03/2021 13:17
March 8 (Reuters) - Alteogen Inc 196170.KQ :
* ALTEOGEN ANNOUNCES COMPLETION OF PHASE 1 CLINICAL TRIAL OF
AFLIBERCEPT BIOSIMILAR IN WET AMD PATIENTS
* ALTEOGEN INC - IN PHASE 1 CLINICAL TRIAL, ALTEOGEN
CONFIRMED
SAFETY AND EFFICACY OF ALT-L9 WERE SIMILAR TO THAT OF EYLEA
* ALTEOGEN INC - INTENDS TO PROVE SIMILARITY OF ALT-L9 WITH
EYLEA
THROUGH A REGISTRATIONAL PHASE 3 CLINICAL TRIAL
Source text for Eikon: ID:nBw71jQFBa
Further company coverage: 196170.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alteogen
See all newsBrief: Alteogen Enters Into A License Agreement With Biogen For Development And Commercialization Of Hybrozyme™-Based Subcutaneous Biologics
Brief: Alteogen Signs Licensing Deal With Biogen International For Alt-B4
Brief: Alteogen 2025 Operating Profit 115 Billion Won, Up 275% From Year Earlier
Brief: Alteogen Signs $285 Million Contract With Gsk Unit
Brief: Alteogen Receives Positive CHMP Opinion For Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'